Insights on the pathogenicity of human T-lymphotropic/leukemia virus types I and II

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 13, Issue SUPPL. 1, 1996, Pages

  Cereseto, Anna ^a   Mulloy, James C ^a   Franchini, Genoveffa ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

HTLV II; Human T lymphotropic leukemia virus type I (HTLV I); T cell transformation

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR;

CARCINOGENICITY; CELL CYCLE; CONFERENCE PAPER; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; PATHOGENESIS; PHYLOGENY; PRIORITY JOURNAL; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE SUBPOPULATION; VIROGENESIS; VIRUS INFECTION;

HTLV; HTLV II; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2;

EID: 0029760422     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199600001-00013     Document Type: Conference Paper

References (81)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77:7415-9.
2. Gallo RC. The first human retrovirus. Sci Am 1986;255:88-98.
3. Miyoshi I, Kubonishi I, Yoshimoto S, et al. Type C virus particles in a cord T cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 1981;294:770-1.
4. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982;79:2031-5.
5. Hinuma Y, Nagata K, Hanaoka M, et al. Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981;78:6476-80.
6. Catovsky D, Greaves MF, Rose M, et al. Adult T-cell leukemia-lymphoma in Blacks from the West Indies. Lancet 1982;1:639-43.
7. Blattner WA, Kalyanaraman VS, Robert-Guroff M, et al. The human type C retrovirus. HTLV in Blacks from the Caribbean region and relationship to adult T-cell leukemia/ lymphoma. Int J Cancer 1982;30:257-64.
8. Yamaguchi K, Takatsuki K. Adult T-cell leukaemialymphoma. Baillieres Clin Haematol 1993;6:899-915.
9. Greenblatt MS, Bennet WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54: 4855-78.
10. Cesarman E, Chadburn A, Inghirami G, Gaidano G, Knowles DM. Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/ lymphoma shows frequent p53 mutations. Blood 1992;80: 3205-16.
11. Sugito S, Yamato K, Sameshima Y, Yokota J, Yano S, Miyoshi I. Adult T-cell leukemia: Structures and expression of the p53 gene. Int J Cancer 1991;49:880-5.
12. Sakashita A, Hattori T, Miller CW, et al. Mutation of the p53 gene in adult T-cell leukemia. Blood 1992;79:477-80.
13. Nagai H, Kinoshita T, Imanura J, et al. Genetic alteration of p53 in some patients with adult T-cell leukemia. Jpn J Cancer Res 1991;82:1421-7.
14. Yamato K, Oka T, Hiroi M, et al. Aberrant expression of the p53 tumor suppressor gene in adult T-cell leukemia and HTLV-1 infected cells. Jpn J Cancer Res 1993;84:4-8.
15. Reid RL, Lindholm PF, Mireskandari A, Dittmer J, Brady JN. Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-I. Oncogene 1993;8:3029-36.
16. Gartenhaus RB, Wang P. Functional inactivation of wild-type p53 protein correlates with loss of IL-2 dependence in HTLV-I transformed human T-lymphocytes. Leukemia (in press).
17. Ceresto A, Diella F, Mulloy JC et al. p53 functional impairment and high expression of p21 waf2/cip2 in human T-cell lymphotropic/leukemia virus type 1 (HTLV-I) transformed T-cells. Blood (in press).
18. Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587-97.
19. Grassman R, Dengler C, Muller-Fleckenstein I, et al. Transformation to continuous growth of primary T-lymphocytes by human T-cell leukemia virus type I X-region genes transduced by herpesvirus Saimiri vector. Proc Natl Acad Sci USA 1989;86:3351-5.
20. Kastan MB, Radin AI, Kuerbitz SJ, et al. Level of p53 protein increase with maturation in human hematopoietic cells. Cancer Res 1991;51:4279-86.
21. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
22. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75: 817-25.
23. Hunter T, Pines J. Cyclins and cancer. Cell 1991;66:1071-4.
24. Reed SI. The role of p34 kinases in the G1 to S-phase transition. Annu Rev Cell Biol 1992;8:529-61.
25. Hunter T. Braking the cell cycle. Cell 1993;75:839-41.
26. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/cdk 4. Nature (London) 1993;366:104-7.
27. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
28. INK4 in human cancer (p53 protein/tumor-suppressor gene/cyclin D1/retinoblastoma protein). Proc Natl Acad Sci USA 1994;91:11045-9.
29. Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M, Koeffler P. Homozygous deletions of the p15(MTS2) and p16 (CDUN2/MTS2) genes in adult T-cell leukemia. Blood 1995;85:2699-704.
30. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
31. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:23-6.
32. Walker GJ, Haluska FG, Flores JF, et al. Characterization of p21 candidate genes in familial melanoma. Am J Hum Genet 1994;55 (Suppl):A73 (abstr).
33. MacGeoch C, Newton Bishop JA, Bataille V, et al. Genetic heterogeneity in familial malignant melanoma. Hum Mol Genet 1994;3:2195-200.
34. ink4 mutations. N Engl J Med 1995;333:970-4.
35. waf1/cip1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-84.
36. Fujii M, Sassone-Corsi P, Verma IM. C-fos promoter transactivation by the tax1 protein of human T-cell leukemia virus type I. Proc Natl Acad Sci USA 1988;85:8526-30.
37. Alexandre C, Charnay P, Verrier B. Transactivation of Krox-20 and Krox-24 promoters by HTLV-I Tax protein through common regulatory elements. Oncogene 1991;6: 1851-7.
38. Fuji M, Miki T, Matsuda T, Matsui M, Nomura N, Seiki M. HTLV-I Tax induces expression of various immediate early serum responsive genes. Oncogene 1991;6:1023-9.
39. MacLeod KF, Sherry N, Hannon G, et al. p53 dependent and independent expression during cell growth, differentiation, and DNA damage. Genes Dev 1995;9:935-44.
40. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53 independent pathway. Cancer Res 1994;54:3391-5.
41. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
42. Franchini G. Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood 1995;86: 3619-39.
43. c. Immunol Rev 1994;61:138-64.
44. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993;73:5-8.
45. Nakamura Y, Russell SM, Mess SA, et al. Heterodimerization of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferation. Nature 1994;369:330-3.
46. Nelson BH, Lord JD, Greenberg PD. Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferation. Nature 1994;369:333-6.
47. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934-7.
48. Kondo M, Takeshita T, Ishii N, et al. Sharing of the interleukin-2 (IL-2) receptor γ chain between receptors for IL-2 and IL-4. Science 1993;262:1874-7.
49. Russell SM, Keegan AD, Harada N, et al. Interleukin-receptor γ chain: a functional component of the interleukin-4 receptor. Science 1993;262:1880-2.
50. Noguchi M, Nakamura Y, Russell SM, et al. Interleukin-2 receptor γ chain: A functional component of the interleukin-7 receptor. Science 1993;262:1877-80.
51. Kondo M, Takeshita T, Higuchi M, et al. Functional participation of the IL-2 receptor γ chain in IL-7 receptor complexes. Science 1994;263:1453-4.
52. Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994;264:965-8.
53. Kimura Y, Takeshita T, Kondo M, et al. Sharing of the IL-2 receptor gamma chain with the functional IL-9 receptor complex. Int Immunol 1995;7:115-20.
54. Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor γ chain mutations results in x-linked severe combined immunodeficiency in humans. Cell 1993;73:147-57.
55. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-21.
56. Taniguchi T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science 1995;268:251-5.
57. Ihle JN, Kerr IM. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 1995;11:69-74.
58. Miyazaki T, Kawahara A, Fujii H, et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 1994;266:1045-7.
59. c chains with Jak1 and Jak3: Implications for XSCID and XCID. Science 1994;266:1042-5.
60. c chain of the IL-2 receptor. Science 1994;266:1039-42.
61. Kawamura J, McVicar DW, Johnston JA, et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Nail Acad Sci USA 1994;91:6374-8.
62. Johnston JA, Kawamura M, Kerken RA, et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 1994;370:151-3.
63. Witthuhn BA, Silvennoinen O, Miura O, et al. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 1994;370:153-7.
64. Lin JX, Migone TS, Tsang M, et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 1995;2:331-9.
65. Hou J, Schindler JU, Henzel WJ, Wong SC, McKnight SL. Identification and purification of human Stat proteins activated in response to interleukin-2. Immunity 1995;2:321-9.
66. Fujii H, Nakagawa Y, Schindler U, et al. Activation of Stat5 by interleukin 2 requires a carboxylterminal region of the interleukin 2 receptor beta chain but is not essential for the proliferative signal transmission. Proc Natl Acad Sci USA 1995;92:5482-6.
67. Johnston JA, Bacon CM, Finbloom DS, et al. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci USA 1995;92:8705-9.
68. Migone TS, Lin JX, Cereseto A, et al. Constitutively activated Jak-STAT pathway in T-cells transformed with HTLV-I. Science 1995;269:79-81.
69. Xu X, Kang SH, Heidenreich O, Okerholm M, O'Shea JJ, Nerenberg MI. Constitutive activation of different Jak tyrosine kinases in human T-cell leukemia virus type I (HTLV-I) Tax protein or virus-transformed cells. J Clin Invest 1995; 96:1548-55.
70. Arya SK, Wong-Staal F, Gallo RC. T-cell growth factor gene: lack of expression in human T-cell leukemia-lymphoma virus-infected cells. Science 1984;223:1086-7.
71. Miyoshi I, Kulonishi I, Yoshimoto S, et al. Type C virus particles in a cord T-cell line derived by cocultivating normal human cord leukocytes and human leukaemic T-cells. Nature 1981;294:770-1.
72. Yoshida M, Seiki M. Recent advances in the molecular biology of HTLV-I: transactivation of viral and cellular genes. Annu Rev Immunol 1987;5:541-59.
73. Ciminale V, Pavlaski GN, Derse D, Cunningham CP, Felber BK. Complex splicing in the human T-cell leukemia virus (HTLV) family of retroviruses: novel mRNAs and proteins produced by HTLV-I. Virology 1992;66:1737-45.
74. Koralnik IJ, Gessain A, Klotman ME, LoMonico A, Berneman ZN, Franchini G. Protein isoforms encoded by the pX region of human T-cell leukemia/lymphotropic virus type I. Proc Natl Acad Sci USA 1992;89:8813-7.
75. Ciminale V, D'Agostino DM, Zotti L, Franchini G, Felber BK, Chieco-Bianchi L. Expression and characterization of proteins produced by mRNAs spliced into X region of the human T-cell leukemia/lymphotropic virus type II. Virology 1995;201:445-69.
76. I protein cooperates with the E5 oncoprotein of bovine papillomavirus in cell transformation and binds the 16 kd subunit of vacuolar H+ATPase. J Viral 1993;67:7701-4.
77. c chains and affects their expression on the cell surface. J Virol 1996;70:3599-605.
78. Petti L, Nilson LA, Dimaio D. Activation of the platelet derived growth factor receptor by the bovine papillomavirus E5 transforming protein. EMBO J 1991;10:845-55.
79. Petti L, DiMaio D. Stable association between the bovine papillomavirus E5 transforming protein and activated platelet-derived growth factor receptor in transformed mouse cells. Proc Natl Acad Sci USA 1992;89:6736-40.
80. Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood 1993;81:2223-6.
81. Ohashi T, Masuda M, Ruscetti SK. Induction of sequence-specific DNA binding factors by erythropoietin and the spleen focus-forming virus. Blood 1995;84:1454-62.